IH
Iguana Healthcare Management, LLC
Diversified strategyHigh-turnover traderSector-focused
Total reported value
$152.0M
Reporting period: 2018-03-31 · Number of holdings: 62
Iguana Healthcare Management, LLC disclosed 62 holdings in its latest 13F filing for the period ending 2018-03-31, with total reported value of $152.0M and a quarterly turnover rate of 91.4%.
Personality snowflake
- Concentration
- 10.76
- Portfolio Stability
- 91.43
- Momentum/Contrarian
- 0
- Sector conviction
- 100
- Diversification
- 100
- Sizing Uniformity
- 91.76
Recent moves
Trim ESPR
-39.4% -$3.6M
Trim 48273J107
-85.7% -$2.7M
Add ARNAEUR
+100.0% $2.3M
Trim BIIB
-20.5% -$2.2M
Trim DERMEUR
0.0% -$2.0M
Trim CI
-20.0% -$1.7M
Holdings Map
New buyAddUnchangedTrim
Top 10 holdings by weight
Full holdings list this quarter
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Spdr S&p 500 ETF Tr | ETF-Large Cap & Growth | 8.66% | +8.66% | NEW | |
| 2 | ESPR | Esperion Therapeutics INC | Stock-Other | 4.76% | -2.32% | -39.39% | |
| 3 | IMMU | Immunomedics INC | Stock-Other | 3.84% | -0.90% | -11.11% | |
| 4 | GBTUSD | Global Blood Therapeutics In | Stock-Other | 3.65% | — | -8.00% | |
| 5 | HUM | Humana INC | Stock-Healthcare | 3.54% | — | -11.11% | |
| 6 | BIIB | Biogen INC | Stock-Healthcare | 3.15% | -1.41% | -20.45% | |
| 7 | MRK | Merck & Co. INC. | Stock-Healthcare | 2.87% | — | — | |
| 8 | ARNAEUR | Arena Pharmaceuticals INC | Stock-Other | 2.60% | +1.49% | +100.00% | |
| 9 | ✓ | Shire PLC | Stock-Other | 2.46% | +2.46% | NEW | |
| 10 | CLVSEUR | Clovis Oncology INC | Stock-Other | 2.43% | — | +16.67% | |
| 11 | ✓ | Esperion Therapeutics INC Ne | Stock-Other | 2.38% | +2.38% | NEW | |
| 12 | ANAB | Anaptysbio INC | Stock-Other | 2.23% | — | -18.75% | |
| 13 | CI | The Cigna Group | Stock-Healthcare | 2.21% | -1.10% | -20.00% | |
| 14 | ✓ | Mylan N V | Stock-Other | 2.17% | +1.07% | +100.00% | |
| 15 | CNC | Centene CORP | Stock-Healthcare | 2.11% | +2.11% | NEW | |
| 16 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 2.08% | — | — | |
| 17 | ALXN | Alexion Pharmaceuticals INC | Stock-Other | 2.02% | +2.02% | NEW | |
| 18 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.01% | — | +20.00% | |
| 19 | ABT | Abbott Laboratories | Stock-Healthcare | 1.97% | -0.82% | -33.33% | |
| 20 | ✓ | Laboratory CORP Amer Hldgs | Stock-Other | 1.86% | +1.86% | NEW | |
| 21 | ADMA | Adma Biologics INC | Stock-Healthcare | 1.82% | — | — | |
| 22 | DXCM | Dexcom INC | Stock-Healthcare | 1.71% | +1.71% | NEW | |
| 23 | ✓ | Gyre Therapeutics INC Com | Stock-Other | 1.70% | +1.70% | NEW | |
| 24 | T8S | Tesaro INC | Stock-Other | 1.69% | — | +28.57% | |
| 25 | ZSANEUR | Zosano Pharma CORP | Stock-Other | 1.66% | +1.66% | NEW | |
| 26 | SGMOQ | Sangamo Therapeutics INC | Stock-Other | 1.56% | — | -16.67% | |
| 27 | RCKT | Rocket Pharmaceuticals INC | Stock-Other | 1.54% | +1.54% | NEW | |
| 28 | GSKH | GSK plc ADRhedged | ETF-Other | 1.54% | +0.85% | +100.00% | |
| 29 | MDCOUSD | Medicines Company | Stock-Other | 1.52% | — | +16.67% | |
| 30 | ✓ | Armo Biosciences INC | Stock-Other | 1.48% | +1.48% | NEW | |
| 31 | ✓ | Spdr Series Trust | Stock-Other | 1.44% | +1.44% | NEW | |
| 32 | SRRAEUR | Sierra Oncology INC | Stock-Other | 1.36% | — | +25.00% | |
| 33 | DPLOEUR | Diplomat Pharmacy INC | Stock-Other | 1.33% | +0.68% | +100.00% | |
| 34 | MYOKEUR | Myokardia INC | Stock-Other | 1.28% | — | -20.00% | |
| 35 | CTMX | Cytomx Therapeutics INC | Stock-Other | 1.22% | — | -13.33% | |
| 36 | IOVA | Iovance Biotherapeutics INC | Stock-Other | 1.11% | +1.11% | NEW | |
| 37 | MRTXEUR | Mirati Therapeutics INC | Stock-Other | 1.11% | +1.11% | NEW | |
| 38 | KPTIEUR | Karyopharm Therapeutics INC | Stock-Other | 1.10% | -0.78% | -58.33% | |
| 39 | VKTX | Viking Therapeutics INC | Stock-Healthcare | 1.08% | — | +66.67% | |
| 40 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.95% | +0.95% | NEW | |
| 41 | ✓ | Merus N V | Stock-Other | 0.91% | — | -25.00% | |
| 42 | VYGR | Voyager Therapeutics INC | Stock-Other | 0.87% | — | +40.00% | |
| 43 | AKAOQ | Achaogen INC | Stock-Other | 0.85% | — | +33.33% | |
| 44 | ✓ | Corium Intl INC | Stock-Other | 0.83% | — | +22.22% | |
| 45 | INCY | Incyte CORP | Stock-Healthcare | 0.82% | — | +50.00% | |
| 46 | CTLTEUR | Catalent INC | Stock-Other | 0.81% | — | — | |
| 47 | CERNCHF | Cerner CORP | Stock-Other | 0.76% | +0.76% | NEW | |
| 48 | ADVMCHF | Adverum Biotechnologies INC | Stock-Other | 0.76% | — | — | |
| 49 | XNCR | Xencor INC | Stock-Other | 0.69% | +0.69% | NEW | |
| 50 | KURA | Kura Oncology INC | Stock-Other | 0.62% | +0.62% | NEW |
1–50 of 62
Reported value over time
Sector allocation
Sector allocation over time
Quarterly history
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2018-03-31 | 62 | $152.0M | 91 | |
| 2017-12-31 | 61 | $153.6M | 63 | |
| 2017-09-30 | 68 | $183.5M | 76 | |
| 2017-06-30 | 62 | $176.9M | 82 | |
| 2017-03-31 | 69 | $202.2M | 77 | |
| 2016-12-31 | 60 | $167.3M | 94 | |
| 2016-09-30 | 74 | $281.3M | 87 | |
| 2016-06-30 | 82 | $245.8M | 100 | |
| 2016-03-31 | 75 | $272.9M | 100 | |
| 2015-12-31 | 64 | $303.9M | 100 | |
| 2015-09-30 | 71 | $254.3M | 84 | |
| 2015-06-30 | 69 | $317.0M | 100 | |
| 2015-03-31 | 62 | $237.7M | 100 | |
| 2014-12-31 | 59 | $206.9M | 75 | |
| 2014-09-30 | 62 | $187.2M | 89 | |
| 2014-06-30 | 64 | $214.4M | 92 | |
| 2014-03-31 | 74 | $216.3M | 100 | |
| 2013-12-31 | 70 | $175.5M | 0 |
Holding changes this quarter
Iguana Healthcare Management, LLC's most significant position changes for 2018-03-31: New buy: Spdr S&p 500 ETF Tr; Sold out: Celgene CORP (CELG); Sold out: Aerie Pharmaceuticals INC (AERIEUR); Sold out: Abbvie INC (ABBV); New buy: Shire PLC.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ARNAEUR | Arena Pharmaceuticals INC | +1.5% | +100.00% | Add |
| 2 | ✓ | Mylan N V | +1.1% | +100.00% | Add |
| 3 | GSKH | GSK plc ADRhedged | +0.9% | +100.00% | Add |
| 4 | DPLOEUR | Diplomat Pharmacy INC | +0.7% | +100.00% | Add |
| 5 | KPTIEUR | Karyopharm Therapeutics INC | -0.8% | -58.33% | Trim |
| 6 | ABT | Abbott Laboratories | -0.8% | -33.33% | Trim |
| 7 | IMMU | Immunomedics INC | -0.9% | -11.11% | Trim |
| 8 | CI | The Cigna Group | -1.1% | -20.00% | Trim |
| 9 | DERMEUR | Dermira INC | -1.3% | — | Unchanged |
| 10 | BIIB | Biogen INC | -1.4% | -20.45% | Trim |
| 11 | ✓ | K2m Group Holdings INC | -1.7% | -85.71% | Trim |
| 12 | ESPR | Esperion Therapeutics INC | -2.3% | -39.39% | Trim |
| 13 | ✓ | Spdr S&p 500 ETF Tr | — | NEW | New buy |
| 14 | CELG | Celgene CORP | — | EXIT | Sold out |
| 15 | AERIEUR | Aerie Pharmaceuticals INC | — | EXIT | Sold out |
| 16 | ABBV | Abbvie INC | — | EXIT | Sold out |
| 17 | ✓ | Shire PLC | — | NEW | New buy |
| 18 | ✓ | Esperion Therapeutics INC Ne | — | NEW | New buy |
| 19 | CNC | Centene CORP | — | NEW | New buy |
| 20 | ALXN | Alexion Pharmaceuticals INC | — | NEW | New buy |
| 21 | ✓ | Laboratory CORP Amer Hldgs | — | NEW | New buy |
| 22 | ✓ | Juno Therapeutics | — | EXIT | Sold out |
| 23 | ZBH | Zimmer Biomet Holdings INC | — | EXIT | Sold out |
| 24 | DXCM | Dexcom INC | — | NEW | New buy |
| 25 | ✓ | Gyre Therapeutics INC Com | — | NEW | New buy |
| 26 | ZSANEUR | Zosano Pharma CORP | — | NEW | New buy |
| 27 | XENTEUR | Intersect Ent INC | — | EXIT | Sold out |
| 28 | RCKT | Rocket Pharmaceuticals INC | — | NEW | New buy |
| 29 | DHR | Danaher CORP | — | EXIT | Sold out |
| 30 | ✓ | Armo Biosciences INC | — | NEW | New buy |
| 31 | ✓ | Spdr Series Trust | — | NEW | New buy |
| 32 | IONS | Ionis Pharmaceuticals INC | — | EXIT | Sold out |
| 33 | SUPN | Supernus Pharmaceuticals INC | — | EXIT | Sold out |
| 34 | PFE | Pfizer INC | — | EXIT | Sold out |
| 35 | WVE | Wave Life Sciences Ltd. | — | EXIT | Sold out |
| 36 | AKCAEUR | Akcea Therapeutics INC | — | EXIT | Sold out |
| 37 | PBYI | Puma Biotechnology INC | — | EXIT | Sold out |
| 38 | ✓ | Clovis Oncology INC | — | EXIT | Sold out |
| 39 | IOVA | Iovance Biotherapeutics INC | — | NEW | New buy |
| 40 | MRTXEUR | Mirati Therapeutics INC | — | NEW | New buy |
| 41 | ✓ | Avexis INC | — | EXIT | Sold out |
| 42 | ✓ | — | EXIT | Sold out | |
| 43 | ✓ | Ablynx NV - Adr | — | EXIT | Sold out |
| 44 | ARWR | Arrowhead Pharmaceuticals In | — | NEW | New buy |
| 45 | BSX | Boston Scientific CORP | — | EXIT | Sold out |
| 46 | CERNCHF | Cerner CORP | — | NEW | New buy |
| 47 | XNCR | Xencor INC | — | NEW | New buy |
| 48 | RGNX | Regenxbio INC | — | EXIT | Sold out |
| 49 | KURA | Kura Oncology INC | — | NEW | New buy |
| 50 | LHCGUSD | Lhc Group INC | — | EXIT | Sold out |
FAQ
What is Iguana Healthcare Management, LLC and what type of investor is it?
Iguana Healthcare Management, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2018-03-31), the firm manages a tracked equity portfolio valued at approximately $152.0M, spread across 62 disclosed positions.
What are Iguana Healthcare Management, LLC's largest equity positions?
Based on the latest 13F filing, Iguana Healthcare Management, LLC's top holdings by market value are:
1. Spdr S&p 500 ETF Tr — $13.2M (8.7%)
2. Esperion Therapeutics INC (ESPR) — $7.2M (4.8%)
3. Immunomedics INC (IMMU) — $5.8M (3.8%)
4. Global Blood Therapeutics In (GBTUSD) — $5.6M (3.6%)
5. Humana INC (HUM) — $5.4M (3.5%)
What changes did Iguana Healthcare Management, LLC make in its most recent portfolio filing?
In the latest reported quarter, Iguana Healthcare Management, LLC made 49 notable position adjustments: 18 new positions were initiated, 4 existing holdings were added to, 7 positions were partially reduced, and 20 were completely exited. The largest of these moves: New buy: Spdr S&p 500 ETF Tr; Sold out: Celgene CORP (CELG); Sold out: Aerie Pharmaceuticals INC (AERIEUR); Sold out: Abbvie INC (ABBV); New buy: Shire PLC
What sectors does Iguana Healthcare Management, LLC focus on?
Iguana Healthcare Management, LLC is concentrated in the following sectors based on its current disclosed equity portfolio:
• Health Care: 100.0%